

CE certification for Myrian® 2.14 advanced visualization solution

Montpellier, France, April 15, 2025, 6:00pm. Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), the French expert in AI-enhanced medical imaging solutions that facilitate and secure diagnosis, decision-making and therapeutic follow-up, announces that it has obtained CE marking under MDR (Medical Device Regulation) for Myrian® 2.14, the new version of its advanced radiology visualization solution. This new CE marking for Intrasense's innovative solutions is fully in line with the Group's strategic roadmap, based on four pillars: innovation, product range extension, geographical expansion and financial control.

Commenting on this certification, **Alexandre Salvador, Intrasense's CEO**, said: *"This new version, focused on optimizations requested by our users, illustrates our determination to guarantee a solution that is ever more efficient, intuitive and in line with market expectations. We are actively pursuing the integration of advanced technologies, in particular artificial intelligence, to offer tools that are even more precise and adapted to clinical needs. Our ambition is clear: to maintain Myrian® as an essential reference in medical imaging, bringing ever greater value to radiologists and clinicians worldwide."*

Following on from 2024, marked by the certification of six major solutions (Myrian® 2.10, 2.12 and 2.13, Liflow® 1.0 and 2.0, DUOnco™ Liver 1.0), Intrasense continues its commitment to innovation. Version 2.14 of Myrian®, which benefits from the most demanding standards in terms of European regulations, mainly integrates optimization of existing modules, notably on user experience and calculation methods. The new version also includes specific updates for senology, notably for tomosynthesis review.

With this update, Myrian® continues to evolve to meet the needs of radiologists, with enhanced stability. R&D teams have also worked on optimizing compatibility and integration with PACS systems and hospital workflows, to make it easier for clinicians to get to grips with the software.

About Intrasense

A French expert in medical imaging since 2004 and a digital subsidiary of the Guerbet Group, Intrasense designs medical imaging software solutions natively enriched by artificial intelligence algorithms.

Myrian®, an advanced radiology visualization platform featuring cutting-edge clinical tools, optimizes and simplifies the interpretation of all types of images. DUOnco™, a range of expert AI algorithms for oncology, offers an AI for the detection of focal liver lesions and the first AI dedicated to CE-marked bone lesions. Liflow®, a dedicated oncology monitoring solution integrating multi-organ AIs, optimizes the longitudinal monitoring of cancer patients.

By combining clinical expertise and operational performance, Intrasense provides healthcare professionals with high medical value tools, facilitating analysis, diagnosis and patient management. **More information on www.intrasense.fr**

Contacts

INTRASENSE

Communication officer

Salomé Sylvestre

Phone : +33 4 67 13 01 30

investisseurs@intrasense.fr

SEITOSEI.ACTIFIN

Analyst & Investor Relations

Foucauld Charavay

Phone : +33 6 37 83 33 19

intrasense@seitosei-actifin.com

Press Relations

Isabelle Dray

Phone : +33 1 56 88 11 29

isabelle.dray@seitosei-actifin.com